Ramlau, Rodryg <br/><br/>
Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial.  [electronic resource] 

 -  Journal of clinical oncology : official journal of the American Society of Clinical Oncology  Oct 2012 
 - 3640-7 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1527-7755 
<br/><br/><label>Standard No.: </label>10.1200/JCO.2012.42.6932  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Carcinoma, Non-Small-Cell Lung--drug therapy<br/>Confidence Intervals<br/>Disease-Free Survival<br/>Docetaxel<br/>Dose-Response Relationship, Drug<br/>Double-Blind Method<br/>Drug Administration Schedule<br/>Female<br/>Humans<br/>Kaplan-Meier Estimate<br/>Lung Neoplasms--drug therapy<br/>Male<br/>Maximum Tolerated Dose<br/>Neoplasm Invasiveness--pathology<br/>Neoplasm Staging<br/>Platinum--therapeutic use<br/>Prognosis<br/>Proportional Hazards Models<br/>Prospective Studies<br/>Receptors, Vascular Endothelial Growth Factor<br/>Recombinant Fusion Proteins--therapeutic use<br/>Risk Assessment<br/>Survival Analysis<br/>Taxoids--therapeutic use<br/>Treatment Outcome